Scinai Immunotherapeutics Ltd. announced that it will receive $1,329,254 in funding on September 19, 2023. The company will issue Convertible Preferred Shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D. In connection with the issuance of warrants to purchase up to 1,146,552 American Depositary Shares ("ADSs"), each representing 400 ordinary shares, no par value, of the Company at an exercise price of $1.16 per ADS.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4578 USD | +1.74% | -1.76% | -23.11% |
1st Jan change | Capi. | |
---|---|---|
-23.11% | 1.99M | |
+1.51% | 42.75B | |
+48.37% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- SCNI Stock
- News Scinai Immunotherapeutics Ltd.
- Scinai Immunotherapeutics Ltd. announced that it expects to receive $1.329254 million in funding